SCHEMBL3635599

SCHEMBL3635599

CCCC(=O)c1ccc(NC(=O)c2ccc(N(C)C)nc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 4/20 0.50
ALDH1A1 P00352 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
LMNA P02545 1/20 0.49
CXCR1 P25024 3/20 0.47
CXCR2 P25025 3/20 0.47
KDM4E B2RXH2 3/20 0.46
RAB9A P51151 3/20 0.46
MAPT P10636 2/20 0.46
TSHR P16473 1/20 0.46
MCL1 Q07820 1/20 0.46
HSD17B10 Q99714 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44
AURKA O14965 1/20 0.43
RPS6KB1 P23443 1/20 0.43
AURKB Q96GD4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3230527 0.81 CXCR2 (0.63) P4HTMALDH1A1KMT2ACXCR1CXCR2
SCHEMBL13201032 0.81 ALDH1A1 (0.65) P4HTMALDH1A1MEN1KMT2ALMNA
SCHEMBL3635601 0.80 L3MBTL1 (0.44) ALDH1A1RAB9AMAPTSMN1; SMN2L3MBTL1
SCHEMBL3634265 0.76 RAB9A (0.69) ALDH1A1KMT2ALMNARAB9AMAPT
SCHEMBL30828557 0.75 P4HTM (0.57) P4HTMLMNARAB9ANPC1
SCHEMBL3978664 0.74 HPGDS (0.50) P4HTMALDH1A1MEN1KMT2ALMNA
SCHEMBL12978160 0.74 LMNA (0.64) LMNARAB9ASMN1; SMN2L3MBTL1NPC1
SCHEMBL9566782 0.73 P4HTM (0.55) P4HTMALDH1A1MEN1KMT2ALMNA
SCHEMBL259419 0.73 MEN1 (0.71) ALDH1A1MEN1KMT2ALMNARAB9A
SCHEMBL3049317 0.73 KMT2A (0.60) P4HTMALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 P4HTM 2284/4885ALDH1A1 3335/4885MEN1 4628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.